FDA and Patent Office team up to speed drug patent approvals
S. 1097 — Interagency Patent Coordination and Improvement Act of 2025 · Filed by Richard Durbin (D-IL) · 4 cosponsors · Introduced Mar 24, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a formal task force between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to share information about drug patents and approvals. Patent examiners will gain access to FDA data on drug approvals, labeling changes, and prior art to make better patenting decisions, while the FDA will receive help organizing patent listings. The bill includes confidentiality protections and requires a report in 4 years on how useful the information-sharing has been.
Why we flagged it
The bill's core function is establishing a formal information-sharing task force between two federal agencies to improve patent examination and drug approval consistency. It is procedural and administrative in nature, not a substantive policy change.
What the text implies
- Patent examiners will gain access to non-public FDA communications and product application data, which may accelerate patent grants for drugs by providing earlier visibility into approval timelines and competitive landscape.
- The 30-day notice requirement gives drug sponsors advance warning of information sharing, potentially allowing them to request confidentiality protections or adjust patent strategy before examiners see sensitive data.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies; biotechnology firms; patent prosecution service providers